Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Vaccines
Filter     Order     Display # 
Date Item Title
06 Nov 2007 GlobeImmune Announces Presentation of Results from a Randomized Phase 1b Study of the GI-5005 Tarmogen in Patients with Chronic Hepatitis C Infection
06 Nov 2007 Presentation of phase IIa results for Cytos Biotechnology’s hypertension vaccine at the American Heart Association Scientific Sessions 2007
05 Nov 2007 Curalogic updates from its Phase III clinical study with the ragweed product
03 Nov 2007 IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients
03 Nov 2007 IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
02 Nov 2007 Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
24 Oct 2007 Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
19 Oct 2007 Sanofi Pasteur receives FDA approval of meningococcal vaccine for children
17 Oct 2007 Interim Safety Data Favorable for Vical's Phase 2 Trial of DNA Vaccine Against CMV
11 Oct 2007 Pharmexa provides update on the development of GV1001
09 Oct 2007 Amorfix Life Sciences develops two vaccines that extend life in Amyotrophic Lateral Sclerosis (ALS) animal model
02 Oct 2007 U.S. Food & Drug Administration approves CSL influenza virus vaccine, for marketing in the U.S.
28 Sep 2007 Phylogica signs asthma research agreement
26 Sep 2007 immatics launches Phase 2 study on cancer vaccine IMA901
26 Sep 2007 Twinstrand Therapeutics Inc. Files IND Application For Immunogen in Ricin Antidote Study
26 Sep 2007 VaxInnate Initiates Phase I Clinical Study of M2e Universal Influenza Vaccine
22 Sep 2007 Vaccination and Enrollment Are Discontinued in Phase II Trials of Merck's Investigational HIV Vaccine Candidate
20 Sep 2007 Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
20 Sep 2007 FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
19 Sep 2007 Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study
18 Sep 2007 Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at Low Dosage
12 Sep 2007 Opexa Therapeutics Gives Update on Phase IIb Trial of Tovaxin® for Treatment of Multiple Sclerosis
12 Sep 2007 Oxford BioMedica Reaches First Milestone in TroVax(T) Collaboration with Sanofi-Aventis
12 Sep 2007 Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
11 Sep 2007 TapImmune Inc. Announces Initiation of Testing on Novel Cancer Vaccine
11 Sep 2007 GenVec to Develop New Malaria Vaccine for the U.S Military
11 Sep 2007 Nventa initiates HspE7 Phase 1 Cervical Dysplasia Trial
08 Sep 2007 MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
07 Sep 2007 Introgen's p53 Immunotherapy Drug Candidate to Advance Into Second Phase 2 Clinical Trial in Small Cell Lung Cancer With National Cancer Institute
07 Sep 2007 Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
06 Sep 2007 Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
06 Sep 2007 Merck: Stimuvax(R) Therapeutic Cancer Vaccine - Phase II Data Highlight Three-Year Survival Results for Lung Cancer Patients
03 Sep 2007 FDA Approves ACAM2000(TM) Vaccine for Protection against Smallpox
31 Aug 2007 Meridian Bioscience, Inc. Announces the Commencement of Phase I/II Clinical Trials of Parvovirus B19 Vaccine
28 Aug 2007 Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
28 Aug 2007 Immutep Announces That ImmuFact(R) IMP321 Has Entered a Phase I Lymphodepletion Therapeutic Vaccine Trial in Metastatic Melanoma
24 Aug 2007 Encouraging Phase II data on HIV vaccine utilizing GenVec technologies presented at Seattle AIDS conference
23 Aug 2007 Achievement in the Development of Hepatitis C Virus Vaccine
22 Aug 2007 Targeted Genetics reports interim Phase II data from HIV/AIDS vaccine clinical trial
21 Aug 2007 NasVax receives Ministry of Health approval for a Phase 1/2a clinical study for improved flu vaccine
20 Aug 2007 Intercell's therapeutic Hepatitis C vaccine meets primary endpoints in Phase II interim analysis
18 Aug 2007 Dendreon announces publication of Phase 1 study highlighting immunologic and clinical activity of Lapuleucel-T (Neuvenge(R)) in advanced breast cancer patients
16 Aug 2007 VGX Pharmaceuticals Announces Initiation of IND-enabling Toxicology Studies
15 Aug 2007 Sinovac Commences Vaccination of Volunteers for the Clinical Research of Pandemic Influenza Vaccine (H5N1)
15 Aug 2007 Application for Rotarix(R) by AVANT's partner, GlaxoSmithKline, is accepted for review by the FDA
09 Aug 2007 Iomai trial shows 100 percent immune response in elderly subjects vaccinated with novel travelers' diarrhea patch vaccine
09 Aug 2007 Biomira and Merck KGaA sign amended and restated collaboration and supply agreements related to Stimuvax(R)
09 Aug 2007 MOLOGEN AG: Treatment permission granted for cancer therapy in India
05 Aug 2007 ImmunoCellular Therapeutics Updates Brain Tumor Vaccine Program Status; First Three Patients Enrolled
02 Aug 2007 Iomai Vaccine Confers Statistically Significant Protection Against Travelers' Diarrhea in Phase 2 Study
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 151 - 200 of 591

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Thrombopoiesis-Stimulating Agents (TPO)

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics